Комбинированная антигипертензивная терапия кандесартаном и индапамидом: обзор доказательной базы в свете появления первой фиксированной комбинации
Аннотация. Артериальная гипертония остается ведущей модифицируемой причиной сердечно-сосудистой смертности и инвалидизации, однако показатели контроля артериального давления во всем мире остаются неудовлетворительными во многом из-за низкой приверженности пациентов лечению. Современные европейские и российские клинические рекомендации отдают предпочтение стартовой антигипертензивной терапии двумя препаратами, предпочтительно в виде фиксированной комбинации в одной таблетке. В настоящем обзоре подробно рассмотрена доказательная база блокатора рецепторов ангиотензина II 1-го типа кандесартана и тиазидоподобного диуретика индапамида в пролонгированной форме, чье сочетание представлено на российском и международном фармрынке единственной фиксированной комбинацией – препаратом Гипосарт И.Ж.Д. Кобалава, А.Ю. Моисеева
Ключевые слова
артериальная гипертония
блокатор рецепторов ангиотензина II
тиазидоподобный диуретик
кандесартан
индапамид
фиксированные комбинации
органопротекция
Список литературы
- Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al.; Peer Review Committee Members. 2025 AHA / ACC / AANP / AAPA / ABC / ACCP / ACPM / AGS / AMA / ASPC / NMA /PCNA / SGIM guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2025;86(18):1567–678.
PMID: 40815242. https://doi.org/10.1016/j.jacc.2025.05.007. Erratum in: J Am Coll Cardiol. 2026;87(23):3379. https://doi.org/10.1016/j.jacc.2026.04.021
- NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: A pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–80.
PMID: 34450083. PMCID: PMC8446938. https://doi.org/10.1016/S0140-6736(21)01330-1. Erratum in: Lancet. 2022;399(10324):520. https://doi.org/10.1016/S0140-6736(22)00061-7
- Artyukhov IP, Grinshtein YI, Petrova MM, Shabalin VV, Ruf RR. Prevalence of arterial hypertension in the Krasnoyarsk Krai (Siberia, Russia). BMC Cardiovasc Disord. 2017;17(1):138.
PMID: 28549412. PMCID: PMC5446734. https://doi.org/10.1186/s12872-017-0559-5
- Maksimov SA, Balanova YA, Shalnova SA, Muromtseva GA, Kapustina AV, Drapkina OM. Regional living conditions and the prevalence, awareness, treatment, control of hypertension at the individual level in Russia. BMC Public Health. 2022;22(1):202.
PMID: 35094684. PMCID: PMC8801098. https://doi.org/10.1186/s12889-022-12645-8
- Churilova E, Shkolnikov VM, Shalnova SA, Kudryavtsev AV, Malyutina S, Nilssen O, et al. Long-term trends in blood pressure and hypertension in Russia: An analysis of data from 14 health surveys conducted in 1975–2017. BMC Public Health. 2021;21(1):2226.
PMID: 34876091. PMCID: PMC8653591. https://doi.org/10.1186/s12889-021-12320-4
- Choudhry NK, Kronish IM, Vongpatanasin W, Ferdinand KC, Pavlik VN, Egan BM, et al.; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Medication adherence and blood pressure control: A Scientific Statement from the American Heart Association. Hypertension. 2022;79(1):e1–e14.
PMID: 34615363. PMCID: PMC11485247. https://doi.org/10.1161/HYP.0000000000000203
- Баланова Ю.А., Драпкина О.М., Куценко В.А., Имаева А.Э., Концевая А.В. Артериальная гипертония в российской популяции в период пандемии COVID-19: гендерные различия в распространенности, лечении и его эффективности. Данные исследования ЭССЕ-РФ3. Кардиоваскулярная терапия и профилактика. 2023;22(S8):105–120. [Balanova YuA, Drapkina OM, Kutsenko VA, Imaeva AE, Kontsevaya AV, Maksimov SA, et al. Hypertension in the Russian population during the COVID-19 pandemic: Sex differences in prevalence, treatment and its effectiveness. Data from the ESSE-RF3 study. Kardiovaskulyarnaya terapiya i profilaktika = Cardiovascular Therapy and Prevention. 2023;22(S8):105–120 (In Russ.)].
EDN: YRUNUX. https://doi.org/10.15829/1728-8800-2023-3785
- Gradman AH, Basile JN, Carter BL, Bakris GL; American Society of Hypertension Writing Group. Combination therapy in hypertension. J Clin Hypertens (Greenwich). 2011;13(3):146–54.
PMID: 21366845. PMCID: PMC8673364. https://doi.org/10.1111/j.1751-7176.2010.00397.x
- King JB, An J, Bellows BK, Cohen JB, Commodore-Mensah Y, Ghazi L, et al.; American Heart Association Council on Hypertension; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Single-pill combination therapy for the management of hypertension: A Scientific Statement from the American Heart Association. Hypertension. 2026;83(3):e00258.
PMID: 41392889. https://doi.org/10.1161/HYP.0000000000000258
- McEvoy JW, McCarthy CP, Bruno RM, Brouwers S, Canavan MD, Ceconi C, et al.; ESC Scientific Document Group. 2024 ESC guidelines for the management of elevated blood pressure and hypertension. Eur Heart J. 2024;45(38):3912–4018.
PMID: 39210715. https://doi.org/10.1093/eurheartj/ehae178. Erratum in: Eur Heart J. 2025;46(14):1300. https://doi.org/10.1093/eurheartj/ehaf031. Erratum in: Eur Heart J. 2025;46(45):4949. https://doi.org/10.1093/eurheartj/ehaf659
- Mancia G, Kreutz R, Brunstrom M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: Endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens. 2023;41(12):1874–2071.
PMID: 37345492. https://doi.org/10.1097/HJH.0000000000003480. Erratum in: J Hypertens. 2024;42(1):194. https://doi.org/10.1097/HJH.0000000000003621
- Кобалава Ж.Д., Конради А.О., Недогода С.В., Шляхто Е.В., Арутюнов Г.П., Баранова Е.И. с соавт. Артериальная гипертензия у взрослых. Клинические рекомендации 2024. Российский кардиологический журнал. 2024;29(9):230–329. [Kobalava ZhD, Konradi AO, Nedogoda SV, Shlyakhto EV, Arutyunov GP, Baranova EI, et al. 024 Clinical practice guidelines for Hypertension in adults. Rossiyskiy kardiologicheskiy zhurnal = Russian Journal of Cardiology. 2024;29(9):230–329 (In Russ.)].
EDN: GUEWLU. https://doi.org/10.15829/1560-4071-2024-6117
- U.S. Food and Drug Administration. Drugs@FDA: FDA-Approved Drugs – Candesartan cilexetil (Atacand), ApplNo 020838.
URL: https://www.accessdata.fda.gov/scripts/cder/daf/ (date of access – 27.08.2026).
- Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Кандесартан (таблетки 8 мг, 16 мг, 32 мг). РУ: ЛП-№(004480)-(РГ-RU) от 01.02.2024. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=608257a9-9844-41b0-b0c2-6901f8227332 (дата обращения – 27.08.2026). [State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the medicinal product Candesartan (tablets 8 mg, 16 mg, 32 mg). Registration certificate: ЛП-№(004480)-(РГ-RU) dated 02/01/2024.
URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=608257a9-9844-41b0-b0c2-6901f8227332 (date of access – 27.08.2026) (In Russ.)].
- Wikipedia. Candesartan. URL https://en.wikipedia.org/wiki/Candesartan (date of access – 27.08.2026).
- Easthope SE, Jarvis B. Candesartan cilexetil: An update of its use in essential hypertension. Drugs. 2002;62(8):1253–87.
PMID: 12010090. https://doi.org/10.2165/00003495-200262080-00016
- Unger T. Significance of angiotensin type 1 receptor blockade: Why are angiotensin II receptor blockers different? Am J Cardiol. 1999;84(10A):9S–15S.
PMID: 10588089. https://doi.org/10.1016/s0002-9149(99)00728-6
- Vanderheyden PM, Fierens FL, Vauquelin G. Angiotensin II type 1 receptor antagonists. Why do some of them produce insurmountable inhibition? Biochem Pharmacol. 2000;60(11):1557–63.
PMID: 11077037. https://doi.org/10.1016/s0006-2952(00)00388-9
- Gring CN, Francis GS. A hard look at angiotensin receptor blockers in heart failure. J Am Coll Cardiol. 2004;44(9):1841–46.
PMID: 15519017. https://doi.org/10.1016/j.jacc.2004.07.044
- Van Liefde I, Vauquelin G. Sartan-AT1 receptor interactions: In vitro evidence for insurmountable antagonism and inverse agonism. Mol Cell Endocrinol. 2009;302(2):237–43.
PMID: 18620019. https://doi.org/10.1016/j.mce.2008.06.006
- Леонова М.В. Сартаны в лечении артериальной гипертонии: преимущества кандесартана. Consilium Medicum. 2019;21(1):25–30. [Leonova MV. Sartans in hypertension treatment: Advantages of candesartan use. Consilium Medicum. 2019;21(1):25–30 (In Russ.)].
EDN: OAZANX. https://doi.org/10.26442/20751753.2019.1.190280
- Minatoguchi S, Aoyama T, Kawai N, Iwasa M, Oda M, Kida K, et al. Comparative effect of candesartan and amlodipine, and effect of switching from valsartan, losartan, telmisartan and olmesartan to candesartan, on early morning hypertension and heart rate. Blood Press. 2013;22 Suppl 1:29–37.
PMID: 23330658. https://doi.org/10.3109/08037051.2013.757844
- Meredith PA, Murray LS, McInnes GT. Comparison of the efficacy of candesartan and losartan: A meta-analysis of trials in the treatment of hypertension. J Hum Hypertens. 2010;24(8):525–31.
PMID: 20016523. https://doi.org/10.1038/jhh.2009.99
- Makani H, Bangalore S, Supariwala A, Romero J, Argulian E, Messerli FH. Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: A meta-analysis. Eur Heart J. 2014;35(26):1732–42.
PMID: 23966312. PMCID: PMC5994844. https://doi.org/10.1093/eurheartj/eht333
- Cernes R, Mashavi M, Zimlichman R. Differential clinical profile of candesartan compared to other angiotensin receptor blockers. Vasc Health Risk Manag. 2011;7:749–59.
PMID: 22241949. PMCID: PMC3253768. https://doi.org/10.2147/VHRM.S22591
- Erbe DV, Gartrell K, Zhang YL, Suri V, Kirincich SJ, Will S, et al. Molecular activation of PPARgamma by angiotensin II type 1-receptor antagonists. Vascul Pharmacol. 2006;45(3):154–62.
PMID: 16765099. https://doi.org/10.1016/j.vph.2006.05.002
- Kakuta H, Kurosaki E, Niimi T, Gato K, Kawasaki Y, Suwa A, et al. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: Drug-target interaction analyses. J Pharmacol Exp Ther. 2014;349(1):10–20.
PMID: 24424487. https://doi.org/10.1124/jpet.113.211722
- Ernsberger P, Koletsky RJ. Metabolic effects of antihypertensive agents: Role of sympathoadrenal and renin-angiotensin systems. Naunyn Schmiedebergs Arch Pharmacol. 2006;373(4):245–58.
PMID: 16783586. https://doi.org/10.1007/s00210-006-0080-3
- Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al.; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): Principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.
PMID: 12714861. https://doi.org/10.1097/00004872-200305000-00011
- Papademetriou V, Farsang C, Elmfeldt D, Hofman A, Lithell H, Olofsson B, et al.; Study on Cognition and Prognosis in the Elderly study group. Stroke prevention with the angiotensin II type 1-receptor blocker candesartan in elderly patients with isolated systolic hypertension: The Study on Cognition and Prognosis in the Elderly (SCOPE). J Am Coll Cardiol. 2004;44(6):1175–80.
PMID: 15364316. https://doi.org/10.1016/j.jacc.2004.06.034
- Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al.; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial. Lancet. 2003;362(9386):772–76.
PMID: 13678870. https://doi.org/10.1016/S0140-6736(03)14284-5
- McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: The CHARM-Added trial. Lancet. 2003;362(9386):767–71.
PMID: 13678869. https://doi.org/10.1016/S0140-6736(03)14283-3
- Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению лекарственного препарата Индапамид ретард (таблетки пролонгированного действия, покрытые пленочной оболочкой, 1,5 мг). РУ: ЛП-№(008372)-(РГ-RU) от 13.01.2025. Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5e36c3f6-7ab1-4501-b150-e0551d1f7020 (дата обращения – 27.08.2026). [State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the medicinal product Indapamide Retard (prolonged-release film-coated tablets, 1.5 mg). Registration certificate: ЛП-No.(008372)-(RG-RU) dated 01/13/2025. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=5e36c3f6-7ab1-4501-b150-e0551d1f7020 (date of access – 27.08.2026) (In Russ.)].
- Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887–98.
PMID: 18378519. https://doi.org/10.1056/NEJMoa0801369
- Rosendorff C, Lackland DT, Allison M, Aronow WS, Black HR, Blumenthal RS, et al.; American Heart Association; American College of Cardiology; American Society of Hypertension. Treatment of hypertension in patients with coronary artery disease: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Society of Hypertension. J Am Coll Cardiol. 2015;65(18):1998–2038.
PMID: 25840655. https://doi.org/10.1016/j.jacc.2015.02.038. Erratum in: J Am Coll Cardiol. 2016;68(16):1822.
https://doi.org/10.1016/j.jacc.2016.08.026
- Gosse P, Sheridan DJ, Zannad F, Dubourg O, Gueret P, Karpov Y, et al. Regression of left ventricular hypertrophy in hypertensive patients treated with indapamide SR 1.5 mg versus enalapril 20 mg: The LIVE study. J Hypertens. 2000;18(10):1465–75.
PMID: 11057435. https://doi.org/10.1097/00004872-200018100-00015
- Roush GC, Abdelfattah R, Song S, Ernst ME, Sica DA, Kostis JB. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis. J Clin Hypertens (Greenwich). 2018;20(10):1507–15.
PMID: 30251403. PMCID: PMC8030834. https://doi.org/10.1111/jch.13386
- London G, Schmieder R, Calvo C, Asmar R. Indapamide SR versus candesartan and amlodipine in hypertension: The X-CELLENT Study. Am J Hypertens. 2006;19(1):113–21.
PMID: 16461202. https://doi.org/10.1016/j.amjhyper.2005.06.027
- Agnoletti D, Zhang Y, Borghi C, Blacher J, Safar ME. Effects of antihypertensive drugs on central blood pressure in humans: A preliminary observation. Am J Hypertens. 2013;26(8):1045–52.
PMID: 23736112. https://doi.org/10.1093/ajh/hpt081
- Vinereanu D, Dulgheru R, Magda S, Dragoi Galrinho R, Florescu M, Cinteza M, et al. The effect of indapamide versus hydrochlorothiazide on ventricular and arterial function in patients with hypertension and diabetes: Results of a randomized trial. Am Heart J. 2014;168(4):446–56.
PMID: 25262253. https://doi.org/10.1016/j.ahj.2014.06.010
- Marre M, Puig JG, Kokot F, Fernandez M, Jermendy G, Opie L, et al. Equivalence of indapamide SR and enalapril on microalbuminuria reduction in hypertensive patients with type 2 diabetes: The NESTOR Study. J Hypertens. 2004;22(8):1613–22.
PMID: 15257186. https://doi.org/10.1097/01.hjh.0000133733.32125.09
- Chalmers J, Mourad JJ, Brzozowska-Villatte R, De Champvallins M, Mancia G. Benefit of treatment based on indapamide mostly combined with perindopril on mortality and cardiovascular outcomes: A pooled analysis of four trials. J Hypertens. 2023;41(3):508–15.
PMID: 36633311. PMCID: PMC9894155. https://doi.org/10.1097/HJH.0000000000003368
- Кобалава Ж.Д., Моисеева А.Ю., Носков С.М., Шохин И.Е., Манько К.С., Тимошина Е.В. Первая российская фиксированная комбинация индапамида ретард и кандесартана: результаты двух исследований фармакокинетики и биоэквивалентности. Кардиология. 2025;65(12):39–50. [Kobalava ZhD, Moiseeva AYu, Noskov SM, Shohin IE, Manko KS, Timoshina EV. The first russian fixed combination of indapamide retard and candesartan: Results of two pharmacokinetic and bioequivalence studies. Kardiologiya = Cardiology. 2025;65(12):39–50 (In Russ.)].
EDN: CUIRAE. https://doi.org/10.18087/cardio.2025.12.n3093
- Thomas JR. A review of 10 years of experience with indapamide as an antihypertensive agent. Hypertension. 1985;7(6 Pt 2):II152–56.
PMID: 4077233. https://doi.org/10.1161/01.hyp.7.6_pt_2.ii152
- Campbell DB. The possible mode of action of indapamide: A review. Curr Med Res Opin. 1983;8 Suppl 3:9–24.
PMID: 6352188. https://doi.org/10.1185/03007998309109832
- Uehara Y, Shirahase H, Nagata T, Ishimitsu T, Morishita S, Osumi S, et al. Radical scavengers of indapamide in prostacyclin synthesis in rat smooth muscle cell. Hypertension. 1990;15(2):216–24.
PMID: 2105910. https://doi.org/10.1161/01.hyp.15.2.216
- Robinson DM, Wellington K. Indapamide sustained release: A review of its use in the treatment of hypertension. Drugs. 2006;66(2):257–71.
PMID: 16451099. https://doi.org/10.2165/00003495-200666020-00011
- Sassard J, Bataillard A, McIntyre H. An overview of the pharmacology and clinical efficacy of indapamide sustained release. Fundam Clin Pharmacol. 2005;19(6):637–45.
PMID: 16313275. https://doi.org/10.1111/j.1472-8206.2005.00377.x
- Leonetti G. Clinical positioning of indapamide sustained release 1.5mg in management protocols for hypertension. Drugs. 2000;59 Suppl 2:27–38; discussion 39–40.
PMID: 10678595. https://doi.org/10.2165/00003495-200059002-00004
- Roush GC, Ernst ME, Kostis JB, Tandon S, Sica DA. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: Antihypertensive and metabolic effects. Hypertension. 2015;65(5):1041–46.
PMID: 25733245. https://doi.org/10.1161/HYPERTENSIONAHA.114.05021
- Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: The Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension. 2011;58(2):155–60.
PMID: 21747047. https://doi.org/10.1161/HYPERTENSIONAHA.111.174383
- Garjon J, Saiz LC, Azparren A, Gaminde I, Ariz MJ, Erviti J. First-line combination therapy versus first-line monotherapy for primary hypertension. Cochrane Database Syst Rev. 2020;2(2):CD010316.
PMID: 32026465. PMCID: PMC7002970. https://doi.org/10.1002/14651858.CD010316.pub3
- Федеральная служба по интеллектуальной собственности. Описание изобретения к патенту RU2865353. Доступ: https://fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2865353&TypeFile=html (дата обращения – 27.08.2026). [Federal Service for Intellectual Property of Russia. Description of the invention for patent RU2865353. URL: https://fips.ru/registers-doc-view/fips_servlet?DB=RUPAT&DocNumber=2865353&TypeFile=html (date of access – 27.08.2026) (In Russ.)].
Об авторах / Для корреспонденции
Жанна Давидовна Кобалава, д. м. н., профессор, член-корреспондент РАН, заведующая кафедрой внутренних болезней с курсом кардиологии и функциональной диагностики им. академика В.С. Моисеева Института клинической медицины, Медицинского института РУДН, Москва, Российская Федерация.E-mail: zkobalava@mail.ru
ORCID: https://orcid.org/0000-0002-5873-1768. Scopus ID: 7004399203. eLibrary SPIN: 9828-5409
Александра Юрьевна Моисеева, к. м. н., ассистент кафедры внутренних болезней с курсом кардиологии и функциональной диагностики им. академика В.С. Моисеева Института клинической медицины, Медицинского института РУДН, Москва, Российская Федерация.
E-mail: moiseyeva.alexandra.y@yandex.ru
ORCID: https://orcid.org/0000-0003-0718-5258. Scopus ID: 57223845075. eLibrary SPIN: 1121-0207
Также по теме
